Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Business Advisory Board
  • Our Science
  • Product Pipeline
    • Overview
    • Alzheimer’s Disease
    • ALS
    • MSA
    • Parkinson’s Disease
    • Posters & Publications
  • News & Media
    • Press Releases
    • Corporate Presentations
    • Events
    • In The News
    • Videos
    • Commentary
    • Podcasts
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Results
  • Stock Data
    • TSX: PMN
    • NASDAQ: PMN
    • Analyst Coverage
  • SEDAR
  • SEC Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Feb 02, 2021 8:30am EST

ProMIS Neurosciences Offers Perspectives on Recent Progress in the Alzheimer’s/Amyloid Field

Jan 12, 2021 6:30am EST

ProMIS Neurosciences Announces Strategic Priorities for 2021

Nov 16, 2020 4:48pm EST

ProMIS Neurosciences Completes Offering of Special Warrants

Nov 11, 2020 6:30am EST

ProMIS Neurosciences Announces Third Quarter 2020 Results

Nov 09, 2020 6:30am EST

ProMIS Neurosciences offers comments on recent FDA Advisory Committee meeting on aducanumab for the treatment of Alzheimer’s disease

Nov 05, 2020 6:30am EST

ProMIS Neurosciences Closes First Tranche of Private Placement

Oct 30, 2020 6:30am EDT

ProMIS Neurosciences’ Dr. Neil Cashman CSO, to Speak at 2020 ALS ONE Research Symposium

Oct 29, 2020 6:30am EDT

ProMIS Neurosciences adds Dr. David Wishart to its Scientific Advisory Board

Oct 23, 2020 6:30am EDT

ProMIS Neurosciences Announces Up to $3 Million Private Placement Offering of Special Warrants

Oct 21, 2020 6:30am EDT

ProMIS Neurosciences Offers its Perspective on the Likelihood of Regulatory Approval of Aducanumab

  • arrow_back
  • 1…
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • …19
  • arrow_forward
  • Email Alerts
  • Contacts
Facebook Linkedin Spotify Twitter
©2023 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy